loading page

Human Hypoxia Models: From Space Medicine to Human Pharmacological Studies
  • +2
  • Titiaan Post,
  • Cayla Denney,
  • Adam Cohen,
  • Jens Jordan,
  • Ulrich Limper
Titiaan Post
Institute of Aerospace Medicine, German Aerospace Center
Author Profile
Cayla Denney
Institute of Aerospace Medicine, German Aerospace Center
Author Profile
Adam Cohen
DDCD Consulting and Leiden University Medical Centre
Author Profile
Jens Jordan

Corresponding Author:jens.jordan@dlr.de

Author Profile
Ulrich Limper
Institute of Aerospace Medicine, German Aerospace Center
Author Profile

Abstract

Space medicine has developed controlled terrestrial models to investigate the impacts on human health and performance, and their application should be expanded to encompass disease conditions involving hypoxia and other factors, in order to make valuable contributions to clinical drug development. Hypoxia, a condition in which the body is deprived of adequate oxygen supply, profoundly affects human physiology at multiple levels and contributes to the pathogenesis of various diseases. Experimental exposure to hypoxic conditions has gained recognition as a valuable model for studying diseases like pulmonary hypertension, chronic obstructive pulmonary disease (COPD), obstructive sleep apnea (OSA), migraine, and kidney disease. The approach may be particularly useful in mechanism-oriented early-stage clinical studies. This review will discuss the ability to mimic or induce these conditions in a controlled laboratory setting using hypoxia, making it a valuable tool for testing the efficacy and safety of new pharmaceutical interventions.
21 Jun 2023Submitted to British Journal of Clinical Pharmacology
21 Jun 2023Submission Checks Completed
21 Jun 2023Assigned to Editor
21 Jun 2023Review(s) Completed, Editorial Evaluation Pending
03 Oct 2023Reviewer(s) Assigned
08 Nov 2023Editorial Decision: Revise Major
31 Jan 20241st Revision Received
08 Feb 2024Submission Checks Completed
08 Feb 2024Assigned to Editor
08 Feb 2024Review(s) Completed, Editorial Evaluation Pending
17 Feb 2024Editorial Decision: Accept